Cerus announces Navy implementation of pathogen-reduction for aphresis platelets
Cerus announced that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers. The Bureau of Medicine and Surgery noted that with the recent history with Zika Virus, Ebola, Chikungunya, Dengue, and Babesia, emerging pathogens continue to threaten the blood supply and that the use of pathogen reduction technologies will preemptively address the risk due to emerging pathogens. All Navy Blood Donor Centers are required to implement the policy to pathogen-reduce platelet components by December 31. Cerus' INTERCEPT Blood Systems is currently the only FDA approved pathogen reduction system commercially available in the U.S. to treat platelets and is in routine use at the Navy Blood Donor Center at Walter Reed National Military Medical Center.